Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Loading...
Loading...
  • Omeros Corporation OMER has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). 
  • The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA. 
  • Omeros concurrently requested a Type A meeting with FDA to resolve any outstanding items.
  • Related Link: Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA.
  • Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA. 
  • It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.
  • Related: Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years.
  • Price Action: OMER shares are up 1.94% at $5.26 during after-hours trading on Wednesday.
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...